Expression and Clinical Significance of PIM1 in Newly Diagnosed Patients with Acute Myeloid Leukemia.

Abstract

Background: This study aimed to evaluate the expression level of proviral integration of Moloney murine leukemia virus 1 (PIM1) in acute myeloid leukemia (AML) and to investigate its clinical significance, including its expression and prognostic value in AML.

Methods: Bone marrow samples were obtained from 80 newly diagnosed AML patients (observation group) and 20 healthy individuals (control group). Clinical and pathological characteristics of AML patients were collected. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to measure PIM1 expression levels in the two groups. The association between PIM1 expression and clinicopathological characteristics and prognosis in AML patients was analyzed. Kaplan-Meier survival curves were used to assess the impact of PIM1 expression on overall survival (OS), while Cox proportional hazards regression was employed to identify prognostic factors in AML patients.

Results: PIM1 expression was significantly higher in AML patients compared to the control group (p < 0.0001). Within the AML cohort, the high PIM1 expression group showed significant differences in gender distribution, FAB classification, treatment response, and prognosis compared to the low PIM1 expression group (p < 0.05). The OS of patients with high PIM1 expression was markedly shorter than that of patients with low PIM1 expression (p < 0.05). Furthermore, high PIM1 expression was identified as an independent risk factor for poor prognosis in AML patients.

Conclusions: PIM1 is overexpressed in AML patients and is associated with adverse clinicopathological characteristics and poor prognosis. PIM1 may serve as a prognostic biomarker and a potential therapeutic target in AML.